[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2913326T - Novos moduladores de recetores de fosfato de esfingosina - Google Patents

Novos moduladores de recetores de fosfato de esfingosina

Info

Publication number
PT2913326T
PT2913326T PT151588878T PT15158887T PT2913326T PT 2913326 T PT2913326 T PT 2913326T PT 151588878 T PT151588878 T PT 151588878T PT 15158887 T PT15158887 T PT 15158887T PT 2913326 T PT2913326 T PT 2913326T
Authority
PT
Portugal
Prior art keywords
phosphate receptors
novel modulators
sphingosine phosphate
sphingosine
modulators
Prior art date
Application number
PT151588878T
Other languages
English (en)
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT2913326T publication Critical patent/PT2913326T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT151588878T 2008-05-14 2009-05-14 Novos moduladores de recetores de fosfato de esfingosina PT2913326T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12760308P 2008-05-14 2008-05-14
US12/465,767 US8796318B2 (en) 2008-05-14 2009-05-14 Modulators of sphingosine phosphate receptors

Publications (1)

Publication Number Publication Date
PT2913326T true PT2913326T (pt) 2020-08-24

Family

ID=41416994

Family Applications (2)

Application Number Title Priority Date Filing Date
PT151588878T PT2913326T (pt) 2008-05-14 2009-05-14 Novos moduladores de recetores de fosfato de esfingosina
PT97628267T PT2291080E (pt) 2008-05-14 2009-05-14 Novos modelamodeladores dos recetores da esfingosina fosfato

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT97628267T PT2291080E (pt) 2008-05-14 2009-05-14 Novos modelamodeladores dos recetores da esfingosina fosfato

Country Status (20)

Country Link
US (8) US8796318B2 (pt)
EP (3) EP2291080B1 (pt)
JP (2) JP5837417B2 (pt)
AU (2) AU2009258242B2 (pt)
CY (2) CY1123338T1 (pt)
DK (1) DK2291080T3 (pt)
EA (1) EA021672B1 (pt)
ES (2) ES2813368T3 (pt)
FI (2) FI2291080T5 (pt)
HR (1) HRP20150982T1 (pt)
HU (2) HUE025984T2 (pt)
LT (1) LTC2291080I2 (pt)
MY (2) MY156381A (pt)
NL (1) NL301065I2 (pt)
NO (1) NO2020034I1 (pt)
NZ (1) NZ589617A (pt)
PL (2) PL2913326T3 (pt)
PT (2) PT2913326T (pt)
SI (1) SI2291080T1 (pt)
WO (1) WO2009151529A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576060A (en) 2006-09-07 2011-11-25 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
JP5451614B2 (ja) 2007-08-17 2014-03-26 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体調節剤としてのピリジン誘導体
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
MX2010005889A (es) 2007-12-10 2010-06-22 Actelion Pharmaceuticals Ltd Derivados de tiofeno como agonistas de s1p1/edg1.
ES2389469T3 (es) 2008-03-07 2012-10-26 Actelion Pharmaceuticals Ltd. Derivados novedosos de aminometilbeceno
PT2913326T (pt) 2008-05-14 2020-08-24 Scripps Research Inst Novos moduladores de recetores de fosfato de esfingosina
MX339144B (es) 2008-06-09 2016-05-13 Univ Muenchen Ludwig Maximilians Nuevas drogas para inhibir la agregacion de proteinas involucradas en enfermedades relacionadas con la agregacion de proteinas y/o enfermedades neurodegenerativas.
US8217028B2 (en) * 2008-06-20 2012-07-10 Glaxo Group Limited 1,2,4-oxadiazole indole compounds
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
NZ591001A (en) 2008-08-27 2012-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
CN102361867A (zh) 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
MX2012000414A (es) 2009-07-16 2012-02-08 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo.
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
MX2012005560A (es) 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
US8507538B2 (en) * 2009-11-13 2013-08-13 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
DK2498611T3 (en) * 2009-11-13 2018-04-16 Celgene Int Ii Sarl SPHINGOSIN-1-PHOSPHATE RECEPTOR MODULATORS AND METHODS FOR CHIRAL SYNTHESIS
AU2015202660B2 (en) * 2009-11-13 2016-10-27 Receptos Llc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2390252A1 (en) * 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
ES2548258T3 (es) * 2010-09-24 2015-10-15 Bristol-Myers Squibb Company Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
AU2012208325B2 (en) 2011-01-19 2016-12-22 Idorsia Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
CN102718726A (zh) * 2011-03-31 2012-10-10 上海铂力生物科技有限公司 作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
WO2012158550A2 (en) * 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9540362B2 (en) 2013-02-20 2017-01-10 Lg Life Sciences Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CN105189487B (zh) * 2013-03-15 2017-12-26 爱杜西亚药品有限公司 吡啶‑4‑基衍生物
CA2921420A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
US9828351B2 (en) * 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
JP6895378B2 (ja) 2015-01-06 2021-06-30 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法
US20180016244A1 (en) 2015-04-06 2018-01-18 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
CN109219597A (zh) 2016-06-14 2019-01-15 苏州科睿思制药有限公司 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
US11028060B2 (en) 2016-08-19 2021-06-08 Receptos Llc Crystalline forms of ozanimod and processes for preparation thereof
WO2018050091A1 (zh) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
JP7086945B2 (ja) 2016-09-29 2022-06-20 レセプトス・リミテッド・ライアビリティ・カンパニー 狼瘡を処置するための化合物および方法
WO2018136893A1 (en) 2017-01-23 2018-07-26 Naqi Logics, Llc Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP7123956B2 (ja) * 2017-02-28 2022-08-23 ヘリオイースト・ファーマシューティカル・カンパニー・リミテッド スピロ化合物およびその使用
WO2018211323A1 (en) * 2017-05-17 2018-11-22 Oppilan Pharma Ltd. Hetercyclic compounds for the treatment of disease
EP3677575A4 (en) 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
KR20210074291A (ko) 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020152718A1 (en) 2019-01-25 2020-07-30 Mylan Laboratories Limited Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
WO2020219207A1 (en) * 2019-04-26 2020-10-29 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
WO2021026479A1 (en) * 2019-08-07 2021-02-11 Stamford, Andrew Small molecule inhibitors of s1p2 receptor and uses thereof
JP2023508907A (ja) 2019-12-20 2023-03-06 テナヤ セラピューティクス， インコーポレイテッド フルオロアルキル－オキサジアゾールおよびその使用
US20230145259A1 (en) * 2020-03-27 2023-05-11 Receptos Llc Sphingosine 1 phosphate receptor modulators
JP2023518967A (ja) * 2020-03-27 2023-05-09 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１ホスフェート受容体モジュレーター
US20230149367A1 (en) * 2020-03-27 2023-05-18 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2021207051A1 (en) * 2020-04-06 2021-10-14 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
US20230233532A1 (en) * 2020-06-26 2023-07-27 The Penn State Research Foundation Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
EP4192817A1 (en) * 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
US11905265B1 (en) * 2023-10-13 2024-02-20 King Faisal University 3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
ES2203061T3 (es) * 1998-01-23 2004-04-01 Sankyo Company Limited Derivados de espiropiperadina.
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
US7220734B2 (en) * 2002-12-20 2007-05-22 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
US7482456B2 (en) 2003-04-30 2009-01-27 Merck Frosst Canada 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005032465A2 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CA2547198A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2005058845A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PL1650186T3 (pl) * 2004-10-22 2008-11-28 Bioprojet Soc Civ Nowe pochodne kwasów dikarboksylowych
JP2008531546A (ja) 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
MX2007015422A (es) * 2005-06-08 2008-02-21 Novartis Ag Oxadiazoles o isoxazoles policiclicos y su uso como ligandos del receptor de s1p.
US8501739B2 (en) 2005-07-04 2013-08-06 High Point Pharmaceuticals, Llc Medicaments
EP1968972B1 (en) * 2005-12-23 2012-11-28 F. Hoffmann-La Roche AG Aryl-isoxazolo-4-yl-oxadiazole derivatives
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MX2009003129A (es) 2006-09-29 2009-04-06 Novartis Ag Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
WO2008064320A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2008076356A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
US20090188269A1 (en) 2008-01-25 2009-07-30 Henkel Corporation High pressure connection systems and methods for their manufacture
PT2913326T (pt) 2008-05-14 2020-08-24 Scripps Research Inst Novos moduladores de recetores de fosfato de esfingosina
LT2913326T (lt) 2008-05-14 2020-09-10 The Scripps Research Institute Nauji sfingozino fosfatų receptorių moduliatoriai

Also Published As

Publication number Publication date
WO2009151529A1 (en) 2009-12-17
WO2009151529A9 (en) 2010-04-08
HUE025984T2 (hu) 2016-05-30
US9382217B2 (en) 2016-07-05
EP3782991A1 (en) 2021-02-24
SI2291080T1 (sl) 2015-11-30
JP2011523412A (ja) 2011-08-11
ES2549761T3 (es) 2015-11-02
US20120329838A1 (en) 2012-12-27
AU2015213309B2 (en) 2016-10-13
AU2009258242A1 (en) 2009-12-17
CY1123338T1 (el) 2020-11-25
CY2020033I2 (el) 2021-01-27
NL301065I1 (pt) 2020-09-30
ES2813368T3 (es) 2021-03-23
PT2291080E (pt) 2015-10-30
US10544136B2 (en) 2020-01-28
EA021672B1 (ru) 2015-08-31
NZ589617A (en) 2012-06-29
US8796318B2 (en) 2014-08-05
AU2009258242B2 (en) 2015-07-16
US20100010001A1 (en) 2010-01-14
US20150057307A1 (en) 2015-02-26
EP2291080A1 (en) 2011-03-09
FIC20200037I1 (fi) 2020-09-24
FI2291080T5 (fi) 2023-11-06
NO2020034I1 (no) 2020-09-29
JP2016041736A (ja) 2016-03-31
MY172105A (en) 2019-11-14
JP5837417B2 (ja) 2015-12-24
MY156381A (en) 2016-02-15
US8466183B2 (en) 2013-06-18
EA201001785A1 (ru) 2011-10-31
EP2291080B1 (en) 2015-08-19
US20180009770A1 (en) 2018-01-11
PL2913326T3 (pl) 2020-11-16
LTC2291080I2 (lt) 2021-09-10
PL2291080T3 (pl) 2015-12-31
US20120329840A1 (en) 2012-12-27
US8530503B2 (en) 2013-09-10
US9975863B2 (en) 2018-05-22
US20120329839A1 (en) 2012-12-27
US20170050941A1 (en) 2017-02-23
US20190084947A1 (en) 2019-03-21
DK2291080T3 (en) 2015-12-07
FI2291080T3 (pt) 2015-10-15
US8481573B2 (en) 2013-07-09
AU2015213309A1 (en) 2015-09-03
EP2913326B1 (en) 2020-07-15
CY2020033I1 (el) 2020-11-25
HRP20150982T1 (hr) 2015-10-23
NL301065I2 (nl) 2020-10-28
EP2913326A1 (en) 2015-09-02
EP2291080A4 (en) 2013-09-11
LTPA2020529I1 (lt) 2020-10-26
HUS2000038I1 (hu) 2020-10-28

Similar Documents

Publication Publication Date Title
HUS2000038I1 (hu) Szfingozin foszfát receptor új modulátorai
IL236272A (en) מאפנני tlrs
IL209306A0 (en) Novel modulators of sphingosine phosphate receptors
EP2344446A4 (en) S1P RECEPTOR MODULATORS
PL2477987T3 (pl) Modulatory receptorów toll-podobnych
EP2344484A4 (en) MODULATORS OF S1P RECEIVERS AND THEIR USE
SI2465492T1 (sl) Sestavi, ki obsegajo modulatorje receptorja sfingosin 1 fosfat (S1P)
HK1213873A1 (zh) 選擇性的雜環 -磷酸鞘氨醇受體調節劑
IL219690A0 (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2166848A4 (en) SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS
IL205044A0 (en) Amide linked modulators of ?? - secretase
IL205041A0 (en) Amine linked modulators of ?? - secretase
AP2859A (en) Modulators of toll-like receptors
EP2297579A4 (en) DETERMINING A DISTRIBUTION